Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VP4896 in Mild-to-Moderate Alzheimer's Disease
NCT00231946Phase 3Completed
- Sponsor
- Voyager Therapeutics
- Start
- Sep 2005
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of leuprolide in Alzheimer's disease (AD) (2 arms), sponsored by Voyager Therapeutics. Primary endpoints: Alzheimer's Disease Assessment Scale - Cognitive Subscale at 50 weeks and Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change at 50 weeks. Started Sep 2005; status: completed.
02
Drugs
leuprolide
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00231946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00231946.